A Drug-drug Interaction Study of Lanabecestat (LY3314814) in Healthy Participants

Completed · Phase 1

Conditions studied: Healthy

In brief

The purpose of this study is to learn about the effect of lanabecestat on how the body absorbs and processes dabigatran etexilate and how dabigatran etexilate affects lanabecestat when they are taken together. This study will last about 28 days and participants will be asked to take an lanabecestat tablet daily for 19 days and a dabigatran etexilate tablet on 3 occasions. Screening is required within 30 days prior to the start of the study.

Key facts

Study ID

NCT02568397

Run by

AstraZeneca

People needed

60

Starts

2015-10-31

Expected to finish

2016-01-31

Last updated by the study team

2019-11-01

Who can join

Age: 18 and older, up to 50. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Overtly healthy males and females

You may not qualify if…

• Eye abnormalities or disease
• History of vitiligo or any skin color disorder
• Have a history psychiatric or brain disease including seizures
• Have smoked within the last 3 months
• Are unwilling to avoid food and drinks containing grapefruit or Seville oranges for the duration of the study
• Have known allergies to dabigatran etexilate and related compounds

Where it is running

• Covance — Dallas, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.